EUVIMEDEUVIMED entdecken
Open Access · CC BY 3.0

A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection

Sankhiros Babapoor, Tobias Neef, Christian Mittelholzer, Theodore Girshick, Antonio Garmendia, Hongwei Shang, Mazhar I Khan, Peter Burkhard

Influenza Research and Treatment · 2011

DOI: 10.1155/2011/126794 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Influenza Research and Treatment, 2011. Verfasst von Sankhiros Babapoor und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathobiology and Veterinary Science, University of Connecticut, 61 North Eagleville Road, Storrs, CT 06268, USA. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 3.0). Gefördert von: U.S. Department of Agriculture, University of Connecticut.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Using peptide nanoparticle technology, we have designed two novel vaccine constructs representing M2e in monomeric (Mono-M2e) and tetrameric (Tetra-M2e) forms. Groups of specific pathogen free (SPF) chickens were immunized intramuscularly with Mono-M2e or Tetra-M2e with and without an adjuvant. Two weeks after the second boost, chickens were challenged with 107.2 EID50 of H5N2 low pathogenicity avian influenza (LPAI) virus. M2e-specific antibody responses to each of the vaccine constructs were tested by ELISA. Vaccinated chickens exhibited increased M2e-specific IgG responses for each of the constructs as compared to a non-vaccinated group. However, the vaccine construct Tetra-M2e elicited a significantly higher antibody response when it was used with an adjuvant. On the other hand, virus neutralization assays indicated that immune protection is not by way of neutralizing antibodies. The level of protection was evaluated using quantitative real time PCR at 4, 6, and 8 days post-challenge with H5N2 LPAI by measuring virus shedding from trachea and cloaca. The Tetra-M2e with adjuvant offered statistically significant ( P < 0.05 ) protection against subtype H5N2 LPAI by reduction of the AI virus shedding. The results suggest that the self-assembling polypeptide nanoparticle shows promise as a potential platform for a development of a vaccine against AI.

Autor:innen und Institutionen

  • Department of Pathobiology and Veterinary Science, University of Connecticut, 61 North Eagleville Road, Storrs, CT 06268, USA.

Förderung

  • U.S. Department of Agriculture
  • University of Connecticut

Zitieren

APA

Babapoor, S., Neef, T., Mittelholzer, C., Girshick, T., Garmendia, A., Shang, H., Khan, M. I., & Burkhard, P. (2011). A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection. Influenza Research and Treatment. https://doi.org/10.1155/2011/126794

Vancouver

Babapoor S, Neef T, Mittelholzer C, Girshick T, Garmendia A, Shang H, et al. A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection. Influenza Research and Treatment. 2011. doi:10.1155/2011/126794

BibTeX
@article{Babapoor2011,
  author = {Babapoor, Sankhiros and Neef, Tobias and Mittelholzer, Christian and Girshick, Theodore and Garmendia, Antonio and Shang, Hongwei and Khan, Mazhar I and Burkhard, Peter},
  title = {A Novel Vaccine Using Nanoparticle Platform to Present Immunogenic M2e against Avian Influenza Infection},
  journal = {Influenza Research and Treatment},
  year = {2011},
  doi = {10.1155/2011/126794}
}
Kostenlos starten →